Daruka Mahadevan, M.D., Ph.D.
Associate Professor of Medicine

Department of Medicine, Hematology/Oncology
Arizona Cancer Center 1969b
P.O. Box: 245024
Tucson, AZ 85724-5024

Phone: 520-626-0191
Fax: 520-626-2225
e-mail: dmahadevan@azcc.arizona.edu
Sunni Beeck, Administrative Assistant, Phone: 626-0191

EDUCATION:

University of Reading, UK, 1982 (BS)

Birkbeck College, UK , 1986 (Ph.D.)
King’s College Hospital Medical Center, UK, 1990 (M.D.)
Mayday University Hospital, UK, 1990 – 1991 (Internship)
Laboratory of Cellular and Molecular Biology, National Cancer Institute, 1991-1994 (Fogarty International Fellowship)
University of Connecticut Health Center, 1994 –1997 (Residency)

HONORS & AWARDS:

AMGEN Fellow of the Year Award, 2000-2001
Dane Foundation Fellowship, British Medical Council, 1998 – 1990

PATENTS:

US Patent #920214.00004 Inhibitors of C-Kit and PDGF Receptor Tyrosine Kinases
US Patent #920214.00003 Anti-CEACAM6 antibodies for the treatment of cancer
US Patent #263922 Aurora 2 Kinase Inhibitors US-2204-2204-96

RESEARCH INTERESTS:

A translational research lab interested in translating basic cancer research findings into patient care. We have projects in areas related to pancreatic, CLL, GIST and prostate cancer. The lab’s expertise is in rational drug design utilizing molecular modeling and identifying new drugs for further applications in cell culture and animal model systems.

STUDENT RESEARCH OPPORTUNITIES:

Participation in animal studies, drug development, grant applications, poster presentations, and manuscript submission for publication.

SELECTED PUBLICATIONS:

Mahadevan D, Cooke L, Riley C, Swart R, Simons B, Della Croce K, Wisner L, Iorio M, Shakalya K, Garewal H, Nagle R, Bearss D. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. Oncogene. 2007 Feb 26; PMID: 17325667 [Epub ahead of print]

Mahadevan D, DiMento J, Croce KD, Riley C, George B, Fuchs D, Mathews T, Wilson C, Lobell M. Transcriptosome and serum cytokine profiling of an atypical case of myelodysplastic syndrome with progression to acute myelogenous leukemia. Am J Hematol. 81(10):779-86, 2006.

Falsey RR, Marron MT, Gunaherath K, Shirahatti N, Mahadevan D, Gunatilake AAL and Whitesell L. Actin microfilament taggregation induced by withaferin A is mediated by Annexin II. Nature Chemical Biology 2005; 2:33-38, 2005.

Cooke L, Grill M, Shirahatti N, Mahadevan D. MDR Transporters as Therapeutic Targets in Cancer. Science & Medicine. 10(1):30-41, 2005.

Mahadevan D. and Shirahatti N. Strategies for Targeting the Multidrug Resistance-1 (MDR1)/P-gp Transporter in Human Malignancies. Current Cancer Drug Targets. 5(6): 445-455, 2005.

List A, Kurtin S, Roe D, Buresh A, Mahadevan D, Fuchs D, Rimsza L, Heaton R, Knight R, Zeldis J. Efficacy of lenalidomide in yelodysplastic syndromes. N Engl J Med. 352(6):549-57, 2005.

SPONSORED THROUGH MSRP:

Kevin Englehardt (MSRP 2005,2006): "Investigation into the Mechanisms of Action of a Cytotoxic Humanized scFv Targeting CEACAM6."

Drew Kurtzman (MSRP 2007): "Targeting Therapies for Gastrointestinal Stromal Tumors Through Drug Administration and siRNA Knockdown."

Last updated: 1/30/2008